Hudson Bay Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
– Sell
-150,000
Closed -$13.5M – 1489
2024
Q4
$13.5M Buy
+150,000
New +$14.5M 0.05% 306
2024
Q2
– Sell
-250,000
Closed -$23.7M – 963
2024
Q1
$23.7M Buy
+250,000
New +$23.2M 0.13% 93
2022
Q3
– Sell
-50,000
Closed -$3.71M – 1383
2022
Q2
$3.71M Buy
+50,000
New +$3.75M 0.03% 565

Other funds holding XBI

Hudson Bay Capital Management's XBI Position: Q2 2026 in Review

Hudson Bay Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2026, closing a stake of 255 shares — an estimated $32.6K sold.

Hudson Bay Capital Management first reported a position in XBI in Q2 2020 and held it in 7 quarters. The position peaked at $11M in Q1 2025. 936 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

  • Hudson Bay Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2026 after selling out during the quarter.
  • Hudson Bay Capital Management sold 255 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $32.6K.
  • Hudson Bay Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2020 and held it in 7 quarters.
  • Hudson Bay Capital Management's State Street SPDR S&P Biotech ETF position peaked at $11M in Q1 2025.
  • 936 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.